• Accueil >
  • Publications >
  • Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE

Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE

1 mars 2021European Journal of Cancer

DOI : 10.1016/j.ejca.2021.01.018

Auteurs

Andrew DJ. Pearson, Steven G. DuBois, Vickie Buenger, Mark Kieran, Kimberly Stegmaier, Pratiti Bandopadhayay, Kelly Bennett, Franck Bourdeaut, Patrick A. Brown, Louis Chesler, Jessica Clymer, Elizabeth Fox, Christopher A. French, Eva Germovsek, Francis J. Giles, Julia G. Bender, Maureen M. Hattersley, Donna Ludwinski, Katarina Luptakova, John Maris, Joe McDonough, Zariana Nikolova, Malcolm Smith, Athanasios C. Tsiatis, Rajeev Vibhakar, Susan Weiner, Joanna S. Yi, Fred Zheng, Gilles Vassal